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Abstract
Background: Endosonography with needle aspiration (EBUS/EUS-NA) is recommended as the first choice for
mediastinal nodal assessment in non-small cell lung cancer (NSCLC). It is important to maintain adequate negative
predictive value of the procedure to avoid unnecessary additional surgical staging, but there are few studies on the
influence of operator-related factors including competency on false negative results. This study aims to compare
the false negative rate of individual operators and whether it changes according to accumulation of experience.
Methods: This is a retrospective study of NSCLC patients who were N0/N1 by EBUS/EUS-NA and confirmed by
pathologic staging upon mediastinal lymph node dissection (n = 705). Patients were divided into a false negative
group (finally confirmed as pN2/N3) and a true negative group (pN0/N1). False negative rates of six operators and
whether these changed according to accumulated experience were analyzed.
Results: There were 111 (15.7%) false negative cases. False negative rates among six operators ranged from 8.3 to
21.4%; however, there were no statistical differences before and after adjustment for patient characteristics and
procedure-related factors (P = 0.346 and P = 0.494, respectively). In addition, false negative rates did not change as
each operator accumulated experience (P for trend = 0.632).
Conclusions: Our data suggest that there would be no difference in false negative rates regardless of which
operator performs the procedure assuming that the operators have completed a certain period of observation and
have performed procedures under the guidance of an expert.
Keywords: Endosonography with needle aspiration (EBUS/EUS-NA), Non-small cell lung cancer, False negative rate,
Operator factor
* Correspondence: myacousticlung@gmail.com
5Division of Pulmonary and Critical Care Medicine, Department of Medicine,
Samsung Medical Center, Sungkyunkwan University School of Medicine,
Irwon-ro 81, Gangnam-gu, Seoul 06351, Republic of Korea
Full list of author information is available at the end of the article
© The Author(s). 2019, corrected publication February 2019. Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s)
and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons
Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in
this article, unless otherwise stated.
Kim et al. BMC Pulmonary Medicine           (2019) 19:14 
https://doi.org/10.1186/s12890-018-0774-6
Introduction
Clinical tumor-node-metastasis (TNM)-staging in
non-small cell lung cancer (NSCLC) is a pivotal factor for
deciding the treatment plan and assessing prognosis [1, 2].
Although computed tomography (CT) and positron emis-
sion tomography (PET) are recommended for evaluation
of TNM staging, invasive mediastinal staging techniques
are still the gold standard approach for confirming
N-staging because imaging techniques have low sensitivity
and specificity to predict metastasis to mediastinal and
hilar lymph nodes (LNs) [1]. Recently, endosonography
(endobronchial ultrasound [EBUS] and esophageal ultra-
sound [EUS]) with needle aspiration (EBUS/EUS-NA) was
recommended as the first choice for mediastinal nodal as-
sessment over surgical staging because of its cost effective-
ness, minimal invasiveness, and high sensitivity for
evaluation of N-stage in patients with NSCLC [1, 3, 4].
However, this recommendation is based on the oper-
ator having appropriate experience and skill level. The
experience of the operator performing the needle biopsy
is known to have a significant impact on the diagnostic
yield [5–7]. Moreover, additional surgical N-staging such
as mediastinoscopy is recommended if the results of
EBUS/EUS-NA are negative but there are suspicions of
mediastinal nodal metastasis because the sensitivity of
EBUS/EUS-NA is not high enough to completely rule
out nodal metastasis [1, 4, 8]. Therefore, it is important
to manage the test quality of EBUS/EUS-NA to achieve
appropriate diagnostic yield, reduce false negative
results, and avoid unnecessary surgical N-staging.
There are many published studies about patient-re-
lated and tumor-related predictors for false negative re-
sults of EBUS/EUS-NA [9, 10], but few reports about
operator-related factors. Although many studies have
evaluated how fast individual trainees adjust to the pro-
cedure as assessed by various evaluation tools [7, 11, 12],
there is a lack of studies analyzing the false negative
rates of EBUS/EUS-NA depending on operator and
using surgical staging as the reference value. In this
study, we aim to evaluate the false negative results of




This study was retrospectively conducted by reviewing
the medical records of patients who had histologically
confirmed primary NSCLC at Samsung Medical Center,
a tertiary referral hospital in South Korea, between
March 2013 and November 2016. Based on CT and PET
images, LN involvement was determined according to
the nodal definition of the International Association for
the Study of Lung Cancer (IASLC) [2]. All patients who
were suspected to have clinical N3, N2, and N1 nodes
which were defined as short-axis of LNs > 1 cm in CT or
maximum standardized uptake value of LNs > 2.5 in
PET [13], or whose tumor was larger than 3 cm or cen-
trally located underwent preoperative tissue confirm-
ation with EBUS/EUS-NA for nodal staging according to
recent guidelines [1, 4].
Over the study period, patients with NSCLC who had
negative results of EBUS/EUS-NA for N2 and N3 were
enrolled. Among these patients, those who did not
undergo definitive surgery with mediastinal dissection or
surgical staging were excluded. We investigated baseline
characteristics of the patients including age, sex, and
location and histologic type of primary tumor, contents
of procedure such as assessed LN station, duration of
procedure, combination of EUS, nodal size, and number
of aspiration and obtained core tissue per node, and final
results of surgical staging. This study was approved by
the Institutional Review Board of Samsung Medical Cen-
ter (IRB No.2017–02–075-011). Informed consent was
waived because of the retrospective nature of the study.
EBUS/EUS-NA
During the study period, there were six operators with
different experience levels of EBUS/EUS-NA (Additional
file 1: Figure S1). We designated the operators as A to F
according to the number of performed procedures. All
operators had at least 2 years of bronchoscopy experience
and started performing the EBUS/EUS-NA procedure in-
dependently without a supervisor after at least 200 cases
of observation and assistance over a period of 6months.
Operator A participated for the entire period of this study
and performed 1228 cases of EBUS/EUS-NA. Of these
cases, 290 cases with negative results of EBUS/EUS-NA
for nodal staging of NSCLC patients were analyzed. Oper-
ators B and D already had many experiences with the
EBUS/EUS-NA procedure at the start of this study, and
performed 1072 and 279 cases of EBUS/EUS-NA during
the study period, respectively. Of these cases, 219 (oper-
ator B) and 67 (operator D) were analyzed for the purpose
of this study, respectively. Operators C, E, and F started
performing the EBUS/EUS-NA procedure in the middle
of the study, and they performed 368, 143, and 84 cases of
EBUS/EUS-NA during the study period, respectively. Of
these cases, 84, 33, and 12 cases were analyzed for oper-
ator C, E, and F, respectively.
EBUS/EUS-NA was performed with a convex probe-
EBUS bronchoscope (BF-UC260F-OL8; Olympus, Tokyo,
Japan) and a 22-gauge needle (NA-201SX-4022; Olympus)
[8, 14]. The mediastinal and hilar LNs were systematically
and completely assessed in the standard sequence from
N3 to N2 to N1 [15]. We have performed EBUS through
the airway, and if necessary, EUS through esophagus using
EBUS scope could be added for the specific LN stations.
However, LNs in N1 were completely evaluated only if a
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patient had a difference in treatment plan depending on N1
metastasis. We performed EBUS/EUS-NA under moderate
sedation with intravenous midazolam and fentanyl. Rapid
on-site cytolopathological examination (ROSE) was not
available during this study period.
To assess the accuracy of EBUS/EUS-NA, final surgi-
cal pathology from mediastinal LN dissection (MLND)
was considered the gold standard. If final surgical path-
ology was N0 or N1, we assessed the result of EBUS/
EUS-NA as true negative. If final surgical pathology was
N2 or N3, we assessed the result of EBUS/EUS-NA as
false negative. LNs with false negative results based on
EBUS/EUS-NA were further classified as attempted LNs,
inaccessible LNs, and unattempted accessible LNs.
Attempted LNs were defined as LNs that were actually
obtained during EBUS/EUS-NA. LNs in stations 3A, 5,
and 6, which are not easily reached with the needle in
EBUS/EUS-NA, were defined as inaccessible [16].
Unattempted accessible LN was defined as an LN that
was easily accessible during the procedure but was not
examined according to the operator’s clinical decision.
Statistical analysis
Data are presented as numbers and percentages for cat-
egorical variables and as means and standard deviations
for continuous variables. Categorical variables were com-
pared using Pearson’s chi-square test or Fisher’s exact test.
Continuous variables were compared using Student’s
T-test or ANOVA test and post-hoc analysis.
Patient characteristics, contents of the procedure, and
false negative results were separately assessed according
to patient and LN. All results were re-analyzed after
excluding patients with false negative results of EBUS/
EUS-NA on the inaccessible LNs when assessed by
patient and after adding unattempted accessible LNs
when assessed by LN.
Multivariable logistic regression analysis was used to
adjust for potential confounding factors in the associ-
ation between false negative results of EBUS/EUS-NA
and operator factors, using operator A as the reference
category. Three models were constructed: Model 1 was
adjusted for patient characteristics such as age, sex, loca-
tion and histologic pattern of tumor; Model 2 was
adjusted for contents of procedure such as duration of
procedure and combination of EUS, and number of eval-
uated lesions for analyzing by patient or nodal size
(short axis), number of aspiration per node, and number
of obtained core tissue per node for analyzing by LN;
Model 3 was adjusted for both patient characteristics
and contents of procedure. We also assessed whether
false negative rates of EBUS/EUS-NA decreased accord-
ing to increased operator experience by the trend test
(Mantel–Haenszel test). All tests were two-sided, and P
values < 0.05 were considered statistically significant. All
Fig. 1 Flow chart. Of 705 enrolled patients, 697 patients underwent definitive surgery with mediastinal dissection, and 8 patients underwent surgical
staging before definitive surgery because they were suspected to have mediastinal metastasis even after confirmation of negative results of EBUS/EUS-NA.
NSCLC, non-small cell lung cancer; EBUS/EUS-NA, endobronchial ultrasonography and esophageal ultrasonography with needle aspiration; LN, lymph node
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data were analyzed using PASW software (IBM SPSS
Statistics ver. 22, Chicago, IL, USA).
Results
Study population
We identified 907 patients with NSCLC who had nega-
tive results to N2 and N3 by EBUS/EUS-NA (Fig. 1).
Among these patients, those who did not undergo de-
finitive surgery with mediastinal dissection or surgical
staging were excluded as follows: 112 patients who re-
ceived definitive radiotherapy and/or chemotherapy, 64
who received best supportive care or were lost to
follow-up, and 26 who underwent surgical resection
without mediastinal dissection. Of 705 patients who had
negative results of EBUS/EUS-NA to N2/3 and under-
went definitive surgery with MLND or surgical staging,
111 (15.7%) had positive results to N2 or N3 from
MLND and were therefore false negative on EBUS/
EUS-NA. These 111 patients were further categorized as
77 (69.4%), 24 (21.6%), and 10 (9.0%) patients with false
negative results to attempted LNs, inaccessible LNs, and
unattempted accessible LNs, respectively.
Patient characteristics
We separately investigated patient characteristics of all
705 included patients and of 681 patients after exclusion
of those who had inaccessible LNs (Table 1). Among all
705 patients, patients with false negative results of
EBUS/EUS-NA were younger and included a higher pro-
portion of females than those with true negative results.
However, there were no statistical differences in tumor
location, histologic type, duration of procedure,
Table 1 Baseline characteristics of all included patients and after exclusion of patients with surgically confirmed metastasis to
inaccessible lymph nodes
All patients Excluding patients with inaccessible LNs
Total True negative False negative P Total True negative False negative P
(n = 705) (n = 594) (n = 111) (n = 681) (n = 594) (n = 87)
Age, year 65.6 ± 8.7 66.2 ± 8.5 62.4 ± 9.0 < 0.001 65.8 ± 8.6 66.2 ± 8.5 62.7 ± 8.7 0.001
Sex, female 171 (24.3) 135 (22.7) 36 (32.4) 0.029 163 (23.9) 135 (22.7) 28 (32.2) 0.054
Location of primary tumor 0.479 0.331
Right 421 (59.7) 360 (60.6) 61 (55.0) 419 (61.5) 360 (60.6) 59 (67.8)
Left 278 (39.4) 229 (38.6) 49 (44.1) 256 (37.6) 229 (38.6) 27 (31.0)
Both 6 (0.9) 5 (0.8) 1 (0.9) 6 (0.9) 5 (0.8) 1 (1.1)
Histologic type 0.255 0.230
Adenocarcinoma 338 (47.9) 277 (46.6) 61 (55.0) 326 (47.9) 277 (46.6) 49 (56.3)
Squamous cell carcinoma 315 (44.7) 273 (46.0) 42 (37.8) 305 (44.8) 273 (46.0) 32 (36.8)
Others 52 (7.4) 44 (7.4) 8 (7.2) 50 (7.3) 44 (7.4) 6 (6.9)
Duration of procedure, min 19.0 ± 7.7 19.1 ± 7.8 18.1 ± 7.0 0.229 19.0 ± 7.8 19.1 ± 7.8 18.5 ± 7.4 0.353
Combination of EUS 69 (9.8) 55 (9.3) 14 (12.6) 0.275 66 (9.7) 55 (9.3) 11 (12.6) 0.319
Numbers of evaluated lesions
Total 3.0 ± 1.0 3.0 ± 1.0 2.8 ± 1.0 0.191 3.0 ± 1.0 3.0 ± 1.0 2.9 ± 1.0 0.510
Mediastinal LNs 2.5 ± 0.9 2.5 ± 0.9 2.4 ± 0.9 0.311 2.5 ± 0.9 2.5 ± 0.9 2.4 ± 0.9 0.677
Hilar LNs 0.5 ± 0.7 0.5 ± 0.7 0.4 ± 0.6 0.590 0.4 ± 0.7 0.5 ± 0.7 0.4 ± 0.6 0.733
Lung parenchymal lesions 29 (4.1) 25 (4.2) 4 (3.6) 1.000 28 (4.1) 25 (4.2) 3 (3.4) 1.000
Time interval between EBUS/EUS-NA
and surgery, day
19.5 ± 14.6 19.4 ± 14.7 19.6 ± 14.1 0.877 19.2 ± 14.3 19.4 ± 14.7 17.7 ± 10.9 0.307
Operator 0.388 0.533
A 290 (41.1) 240/290 (82.8) 50/290 (17.2) 282 (41.4) 240/282 (85.1) 42/282 (14.9)
B 219 (31.1) 187/219 (85.4) 32/219 (14.6) 209 (30.7) 187/209 (89.5) 22/209 (10.5)
C 84 (11.9) 66/84 (78.6) 18/84 (21.4) 79 (11.6) 66/79 (83.5) 13/79 (16.5)
D 67 (9.5) 60/67 (89.6) 7/67 (10.4) 66 (9.7) 60/66 (90.9) 6/66 (9.1)
E 33 (4.7) 30/33 (90.9) 3/33 (9.1) 33 (4.8) 30/33 (90.9) 3/33 (9.1)
F 12 (1.7) 11/12 (91.7) 1/12 (8.3) 12 (1.8) 11/12 (91.7) 1/12 (8.3)
Data are presented as number (%) or mean ± standard deviation
LN lymph node, EUS esophageal ultrasonography, EBUS/EUS-NA endobronchial ultrasonography and esophageal ultrasonography with needle aspiration
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combination of EUS, and number of evaluated lesions by
EBUS/EUS-NA between the true and false negative
groups. These findings remained even after excluding
patients who had inaccessible LNs. Finally, false negative
rates of EBUS/EUS-NA to N2/3 varied from 8.3 to
21.4%, but there were no statistical differences according
to the operator in either setting (P = 0.388 for all pa-
tients; P = 0.533 excluding patients with inaccessible
LNs).
In analysis by operator, there were no statistical
differences in patient characteristics of age, sex,
tumor location, and histologic type across operators
A to F (Additional file 1: Table S1). However, there
were significant differences in procedure-related fac-
tors of procedure time (range from 16.7 ± 5.5 min for
operator C to 34.2 ± 15.2 min for operator E, P <
0.001), frequency of EUS combination (1.2% for oper-
ator C to 18.2% for operator E, P = 0.007), and num-
ber of evaluated lesions (2.5 ± 0.6 for operator D to
3.7 ± 1.1 for operator E, P < 0.001). These findings
persisted after excluding patients who had inaccessible
LNs (Additional file 1: Table S2).
Lymph node characteristics
We separately investigated LN characteristics of 1737
attempted LNs and all 1747 LNs including unattempted ac-
cessible LNs (Table 2). There were 10 unattempted access-
ible LNs with false negative results (station 7 [n = 5], 4R [n
= 4], and 2R [n = 1]), which were all less than 5mm in
short-axis on the CT image. Of 1737 attempted LNs, 78
(4.5%) had false negative results of EBUS/EUS-NA. False
negative rates were low in station 4 L (5/408, 1.2%); average
in stations 2R (4/118, 3.4%), 7 (33/617, 5.3%), and 4R (33/
558, 5.9%); and high in stations 5 (2/12, 16.7%) and 8 (1/8,
12.5%). LNs showing false negative results tended to be lar-
ger in the short axis. Finally, false negative rates of EBUS/
EUS-NA to N2/3 varied from 2.5 to 7.5%, but there were
no statistical differences according to the operator in either
setting (P = 0.250 for attempted LNs; P = 0.409 including
unattempted accessible LNs).
Table 2 Baseline characteristics of attempted lymph nodes only and after inclusion of unattempted accessible lymph nodes
Attempted LNs Including unattempted accessible LNs
Total True negative False negative P Total True negative False negative P
(n = 1737) (n = 1659) (n = 78) (n = 1747) (n = 1659) (n = 88)
Nodal station 0.004 0.001
7 617 (35.5) 584/617 (94.7) 33/617 (5.3) 622 (35.6) 584/622 (93.9) 38/622 (6.1)
4R 558 (32.1) 525/558 (94.1) 33/558 (5.9) 562 (32.2) 525/562 (93.4) 37/562 (6.6)
4L 408 (23.5) 403/408 (98.8) 5/408 (1.2) 408 (23.4) 403/408 (98.8) 5/408 (1.2)
2R 118 (6.8) 114 (96.6) 4/118 (3.4) 119 (6.8) 114/119 (95.8) 5/119 (4.2)
5 12 (0.7) 10 (83.3) 2/12 (16.7) 12 (0.7) 10/12 (83.3) 2/12 (16.7)
8 8 (0.5) 7 (87.5) 1/8 (12.5) 8 (0.5) 7/8 (87.5) 1/8 (12.5)
1R 6 (0.3) 6/6 (100) 0/6 (0) 6 (0.3) 6/6 (100) 0
9 5 (0.3) 5/5 (100) 0/5 (0) 5 (0.3) 5/5 (100) 0
3 3 (0.2) 3/3 (100) 0/3 (0) 3 (0.2) 3/3 (100) 0
2L 2 (0.1) 2/2 (100) 0/2 (0) 2 (0.1) 2/2 (100) 0
Node size, mm
Short axis 7.9 ± 2.8 7.8 ± 2.8 8.6 ± 3.5 0.065 7.9 ± 2.8 7.8 ± 2.8 8.6 ± 3.4 0.058
Long axis 12.0 ± 4.9 12.0 ± 4.9 13.1 ± 5.7 0.084 12.0 ± 4.9 12.0 ± 4.9 13.0 ± 5.5 0.058
Number of aspiration per node 1.6 ± 0.7 1.6 ± 0.7 1.7 ± 0.8 0.142 1.6 ± 0.7 1.6 ± 0.7 1.6 ± 1.0 0.474
Obtained core tissue per node 1.4 ± 0.6 1.3 ± 0.6 1.5 ± 0.6 0.017 1.3 ± 0.6 1.3 ± 0.6 1.3 ± 0.7 0.886
Operator 0.250 0.409
A 787 (45.3) 747/787 (94.9) 40/787 (5.1) 791 (45.3) 747/791 (94.4) 44/791 (5.6)
B 483 (27.8) 467/483 (96.7) 16/483 (3.3) 487 (27.9) 467/487 (95.9) 20/487 (4.1)
C 185 (10.7) 172/185 (93.0) 13/185 (7.0) 186 (10.6) 172/186 (92.5) 14/186 (7.5)
D 162 (9.3) 158/162 (97.5) 4/162 (2.5) 163 (9.3) 158/163 (96.9) 5/163 (3.1)
E 92 (5.3) 88/92 (95.7) 4/92 (4.3) 92 (5.3) 88/92 (95.7) 4/92 (4.3)
F 28 (1.6) 27/28 (96.4) 1/28 (3.6) 28 (1.6) 27/28 (96.4) 1/28 (3.6)
Data are presented as number (%) or mean ± standard deviation
LN lymph node, EUS esophageal ultrasonography
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In analysis by operator, there were no statistical differ-
ences in the proportion of examined LN stations across op-
erators A to F (Additional file 1: Table S3). However, there
were significant differences in the short axis of LN (ranging
from 6.9 ± 2.5mm for operator B to 9.0 ± 2.1mm for oper-
ator F, P < 0.001) and procedure-related factors such as
Fig. 2 We separately investigated odds ratio of false negative results for (a) all 705 included patients and (b) 681 patients after exclusion of those
who had inaccessible lymph nodes. Odds ratio of false negative results according to operator when analyzing by patient, with operator A as a
reference (Details are on Additional file 1: Table S5). Model 1: adjusted for patient character such as age, sex, location and histologic pattern of
tumor; Model 2: adjusted for contents of procedure such as duration of procedure, combination of EUS, and number of evaluated lesions; Model
3: adjusted for both patient character and contents of procedure. EUS = esophageal ultrasound
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Fig. 3 We separately investigated odds ratio of false negative results for (a) 1737 attempted lymph nodes and (b) all 1747 lymph nodes including
unattempted accessible lymph nodes. Odds ratio of false negative results according to operator when analyzing by lymph node, with operator A
as a reference (Details are on Additional file 1: Table S6). Model 1: adjusted for patient character such as age, sex, location and histologic pattern
of tumor; Model 2: adjusted for contents of procedure such as duration of procedure, combination of EUS, nodal size (short axis), number of
aspiration per node, and number of obtained core tissue per node; Model 3: adjusted for both patient character and contents of procedure.
EUS = esophageal ultrasound
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number of punctures per node (1.4 ± 0.5 for operator D to
2.0 ± 1.1 for operator E, P < 0.001) and obtained core tissue
per node (1.2 ± 0.5 for operator D to 1.8 ± 0.8 for operator
E, P < 0.001). These findings persisted after inclusion of un-
attempted accessible LNs (Additional file 1: Table S4).
False negative rate according to operator
We calculated the odds ratios for false negative rate by pa-
tient (Fig. 2 and details in Additional file 1: Table S5) and
LN (Fig. 3 and details in Additional file 1: Table S6) ac-
cording to operator using operator A as a reference. There
were no statistically significant differences in the odds ra-
tios for false negative rate according to operator across the
crude model to model 1 (adjusted for patient characteris-
tics), model 2 (adjusted for contents of procedure), and
model 3 (adjusted for both patient characteristics and con-
tents of procedure) when analyzing by patient and by LN.
We also investigated whether the false negative rate
changed according to the operator’s experience for all
705 patients (Fig. 4a) and for 681 patients after exclud-
ing 24 patients who had inaccessible LNs (Fig. 4b).
There were no statistically significant trends in false
negative rates according to experience for all operators.
Discussion
We retrospectively identified 705 patients with NSCLC
who had negative N2/3 by EBUS/EUS-NA performed by
six operators and subsequently underwent MLND. This
study population included 111 (15.7%) false negative cases.
In our institution, an operator can independently perform
EBUS/EUS-NA without a supervisor after at least 200
cases of observation and assistance over a period of 6
months. Nevertheless, procedure-related factors such as
duration of procedure, frequency of combination with
EUS, number of evaluated lesions, node size, and obtained
core tissue per node varied among operators. There were
no statistically significant differences in baseline character-
istics of age, sex, location of primary tumor, histologic
type, and evaluated nodal station according to operator.
False negative rates to N2/3 LNs according to operator
were not statistically different. In addition, there was no
trend in the change of false negative rate according to ac-
cumulation of operator experience. Therefore, although
there are differences in procedure style according to oper-
ator, there appears to be no difference in false negative
rates after the operator has completed sufficient training.
In the present study, the rate of false negative results on
N2/3 LNs by EBUS/EUS-NA was 111/705 (15.7%). Among
the patients with false negative results, 24/111 (21.6%) had
false negative results to inaccessible LNs, and these rates
were similar to those reported in previous studies [9, 10].
Previous studies have identified several factors associated
with false negative results of EBUS/EUS-NA [9, 10, 17], in-
cluding primary tumor location (central or left lung), ab-
normal findings of mediastinal LNs on CT and/or PET,
inadequacy of the sampling, internal necrosis in the LNs,
and rare cancer types. Although we did not perform multi-
variate analysis to identify the independent patient and
tumor characteristics associated with false negative results,
young age, female gender, inaccessible stations by EBUS,
and larger size of LNs had a trend for higher false negative
rates (Tables 1 and 2).
There are several studies on the learning curve of EBUS/
EUS-NA. Some studies have concluded that optimal accur-
acy of the procedure can be achieved after a relatively short
learning curve (about 10 procedures) [12, 18]. However, an-
other study demonstrated that the minimal diagnostic yield
was achieved with 60 procedures, but optimal results were
obtained after 100 procedures [19]. In another study,
significant variation was seen in the learning curves of
Fig. 4 Change in false negative rates according to accumulation of operator experience. Experience of each operator for EBUS/EUS-NA is shown
in Additional file 1: Figure S1. There were no statistically significant trends in the change of false negative rates when analyzed for all 705 patients
(a) and for 681 patients excluding the 24 patients who had false negative results to inaccessible lymph nodes (b)
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individual operators, with ongoing improvement in EBUS/
EUS-NA skill even after 200 clinical cases [7]. In the
present study, there was no difference in the false negative
rate among the operators despite differences in procedure
style. The differences in interpretation of the learning curve
for operators between these studies may be explained by
the fact that most of the previous studies involved EBUS
novices, whereas our study was conducted on operators
with experience of observation and assistance for least 200
cases. Recent research showed that simulation-based train-
ing using an assessment tool is effective for improving the
EBUS performance metrics [11, 20, 21]. However, no study
has evaluated whether the skills demonstrated on a simula-
tion assessment are transferred to an improvement in
clinical skills as performed in patients [22]. We think that
sufficient clinical experience, even indirect experience such
as observation and assistance, is necessary to increase the
diagnostic performance in real clinical practice.
There are several limitations of this study that affect
the generalizability of our results. First, this is a retro-
spective study performed in only one hospital, and
EBUS/EUS-NA was performed without general
anesthesia or ROSE. However, we evaluated cases per-
formed by six operators with various degrees of experi-
ence and different operator characteristics such as
duration of procedure, frequency of combination with
EUS, number of evaluated lesions, node size, and ob-
tained core tissue per node. We think that the variation
in operator characteristics may overcome some of the
limitations associated with single-institution research.
Second, we were not able to evaluate the complication
rate according to each operator and experience accumu-
lation. Third, we have no data on false negative rates to
N1 LNs. Although differentiation between N0/1 and N2/
3 is the most important factor in N-staging of NSCLC
because it greatly influences the decision of treatment
policy, some recent papers report that differentiation
between N0 and N1 is also important because it may
influence delicate decisions such as neoadjuvant clin-
ical trials for stage II NSCLC, selective MLND, and
selective limited resection [23, 24]. Therefore, further
research is needed to evaluate the false negative rates
to N1 LNs. Finally, we did not confirm whether 200
cases of observation and assistance during 6 months
is the optimum training for the EBUS/EUS-NA
procedure.
Conclusions
In conclusion, if the operator has sufficient experience
of bronchoscopy and at least 6 months of experience of
observation and assistance in EBUS/EUS-NA, the false
negative rate to N2/3 LNs might be not affected by the
operator. In addition, false negative rates to N2/3 LNs
may not be reduced by additional experience. However,
further studies are needed to evaluate the minimum
amount of observation and assistance required before
performing the independent EBUS/EUS-NA procedure.
Additional file
Additional file 1: Figure S1. Experience of each operator with EBUS/
EUS-NA. Table S1. Baseline characteristics, contents of the procedure,
and false negative rate of the total 705 patients analyzed by each
operator. Table S2. Baseline characteristics, contents of the procedure,
and false negative rate of 681 patients, excluding 24 patients who had
false negative result from inaccessible LNs, analyzed by each operator.
Table S3. Baseline characteristics, contents of the procedure, and false
negative rate of the total 1,737 attempted LNs analyzed by each
operator. Table S4. Baseline characteristics, contents of the procedure,
and false negative rate of 1,747 attempted LNs (including 10
unattempted accessible LNs) analyzed by each operator. Table S5. Odds
ratios for false negative results by operator analyzed by patient with
operator A as reference. Table S6. Odds ratios for false negative results
by operator analyzed by LN with operator A as reference. (ZIP 91 kb)
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